Navigation Links
Study focuses on mephedrone use in Northern Ireland post-ban
Date:10/3/2010

Researchers at Queen's University Belfast have completed one of the first studies of mephedrone use in Northern Ireland since the drug was outlawed earlier this year. They found that the ban did not deter those mephedrone users surveyed from taking the substance.

Interviews with 23 mephedrone users were completed during a two-month period (May and June 2010) following the legislation that made the drug illegal in the UK. Study participants were aged 19 to 51 years, around half of whom (12) were female. 19 of the 23 people who took part in the study were employed, and most occupations were affiliated with business, trades, the service industry or the public sector.

The research was led by Dr Karen McElrath at Queen's School of Sociology, Social Policy and Social Work.

The key findings from the study were:

  • 21 of the 23 study participants had used mephedrone after the ban.
  • Only one person was very much opposed to using the substance again.
  • Approximately half the sample preferred mephedrone to cocaine or ecstasy. Some had experienced negative effects, for example, sleeplessness, difficult comedowns and next-day depression, but these factors generally did not deter them from using the substance again.
  • None of those who took part in the research felt that 'legal highs' were safe simply because they were legal.
  • None of the study participants recalled an initial interest in using mephedrone because it had been legal. Rather, its legality before April 2010 meant that it was easier to access and cheaper than many illegal substances.
  • Prior to the ban, only three interviewees had purchased mephedrone from 'head shops' and four interviewees had purchased mephedrone from online suppliers. The majority tended to access mephedrone through friends or dealers.
  • The majority of interviewees had prior experience of taking ecstasy, amphetamine or cocaine.
  • During their most recent use of mephedrone, all the study participants had also consumed alcohol, although the timing and amount of alcohol varied.
  • During their most recent use of mephedrone, six of the 23 participants had used another psychoactive substance, other than alcohol.
  • During their most recent use of mephedrone, most participants had consumed between one-two grams of the drug, although half recalled bingeing on mephedrone, sharing upward of seven-eight grams with two to three other people.

Dr McElrath said: "This is one of the first studies into mephedrone use in Northern Ireland since it was made illegal earlier this year. The findings suggest that the ban did not have a significant impact on those who already used mephedrone, at least during the two-month period that followed the ban. We are keen to develop this research further and to compare our results with a similar study conducted in Waterford prior to the ban on mephedrone in the Republic of Ireland in May 2010."

The study was part of a cross-border research partnership with Marie Clare Van Hout at the Waterford Institute of Technology.


'/>"/>

Contact: Anne-Marie Clarke
anne-marie.clarke@qub.ac.uk
44-028-909-75320
Queen's University Belfast
Source:Eurekalert

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
3. TV drama can be more persuasive than news program, study finds
4. Study carried out into biological risks of eating reptiles
5. Neuroimaging study may pave way for effective Alzheimers treatments
6. Study finds racial gaps continue in heart disease awareness
7. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
8. First blinded study of venous insufficiency prevalence in MS shows promising results
9. Soothing infants with food focus of childhood obesity study
10. People with anxiety disorder less able to regulate response to negative emotions, study shows
11. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Sharon Kleyne, host of the nationally syndicated radio ... on Voice of America, declared on her radio program in November 2016 the need ... when these bullies attack leaders in corporate America, they are trying to take advantage ...
(Date:12/7/2016)... ... December 07, 2016 , ... 1105 Media’s Live ... the Folio: Marketing Awards competition. Live From won in the Use of Social ... and ultimately successful projects undertaken by the media industry’s most innovative marketing professionals. ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, LA.c., a ... Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with ... help patients realize their family building goals. Acupuncture helps fertility patients ...
(Date:12/7/2016)... NORFOLK, Va. (Dec. 3, 2016) , ... (PRWEB) ... ... the nation’s only patient advocacy nonprofit for individuals impacted by cerebral cavernous angiomas, ... work in New Mexico with a patient engagement program. New Mexico has more ...
(Date:12/6/2016)... ... December 06, 2016 , ... People ... can be seen on a type of MRI, according to a study appearing ... of the central nervous system characterized by tremors or trembling and stiffness in ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Dec. 6, 2016   AlloSource , one ... bone, skin and soft-tissue allografts for use in ... Process Manager, for being named to the Board ... Quality Award by the Commerce Department,s National Institute ... commitment to process excellence. The Baldrige Award is ...
(Date:12/6/2016)... , Dec. 6, 2016   ... clinical-stage medical dermatology and aesthetics company, today ... privately held specialty pharmaceutical company focused on ... skin conditions, including psoriasis, atopic dermatitis and ... agreement, Sienna will make an undisclosed upfront ...
(Date:12/6/2016)... 6, 2016  Blueprint Medicines Corporation (NASDAQ: ... kinase medicines for patients with genomically defined diseases, today ... of $125,000,000 million in shares of its common stock. ... a 30-day option to purchase up to an additional ... in connection with the public offering. All shares of ...
Breaking Medicine Technology: